Invex Therapeutics Ltd (ASX:IXC)

Invex Therapeutics Revenue

In the fiscal year ending June 30, 2026, Invex Therapeutics had annual revenue of 46.83K AUD, down -79.56%. Invex Therapeutics had revenue of 46.83K in the half year ending June 30, 2026, a decrease of -96.14%.

• Revenue: 46.83K
• Revenue Growth: -79.56%
• P/S Ratio: 184.57
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 8.64M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	46.83K	-182.26K	-79.56%
Jun 30, 2025	229.08K	-983.17K	-81.10%
Jun 30, 2024	1.21M	753.17K	164.06%
Jun 30, 2023	459.09K	276.83K	151.90%
Jun 30, 2022	182.25K	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 15, 2026

Data Sources Report a data error